title: [Inhibition of malignant ascites with endostatin adenoviral vector].
abstract: OBJECTIVE
  To evaluate the therapeutical effect of endostatin adenoviral vector on malignant ascites and compare it with the combined effect of ad-endostatin and DDP.
  
  
  METHODS
  We transfected SKOV3 cells with ad-endostatin to inhibit human umbilical vein endothelial cells (HUVEC) proliferation. Then we administered ad-endostatin intraperitoneally in BALB/c mice to detect the serum endostatin expression and in the mice with malignant ascites to evaluate the therapeutic efficacy.
  
  
  RESULTS
  Recombinant endostatin inhibited HUVEC proliferation. Endostatin was expressed in serum after intraperitoneal injection of ad-endostatin. The effects of endostatin on inhibition of the ascites accumulation and peritoneal capillary permeability, on demotion of VEGF protein level and microvascular density in tumor tissues, on reduction of the number of red cells and tumor cells counted in malignant ascites, and on prolongation of mice survival were significant in two different malignant ascites. Furthermore, the combination of ad-endostatin with DDP increased the therapeutic efficacy.
  
  
  CONCLUSIONS
  These data suggested that endostatin gene therapy may represent a potential new treatment for malignant ascites, and the therapeutic efficacy can be enhanced by a combination of ad-endostatin with chemotherapy.
authors.affiliation: Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
authors.forename: Min
authors.initials: M
authors.lastname: Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Yang
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Yu-quan
authors.initials: YQ
authors.lastname: Wei
authors.forename: Xia
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001201:Ascites / Q000209:etiology / Q000517:prevention & control*; D043169:Endostatins / Q000235:genetics* / Q000627:therapeutic use; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000150:complications / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000150:complications; D011897:Random Allocation; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D043169:Endostatins; D011994:Recombinant Proteins